Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Nov 9, 2010

23andMe Secures $22M in Series C Round

  • 23andMe raised over $22 million in its Series C financing round. Investors included Johnson & Johnson Development, New Enterprise Associates, and Google Ventures.

    “We believe this round of financing will help us achieve our goal of dramatically accelerating the pace of research that could ultimately make healthcare research and healthcare delivery more efficient,” says Anne Wojcicki, CEO of 23andMe.

    23andMe was founded in 2006 to focus on personal genetics. The company offers DNA analysis technologies and web-based interactive tools. Its Personal Genome Service™ enables individuals to gain insights into their ancestry and inherited traits.

    The firm officially launched its services in the U.S. in November 2007. In January 2008, it expanded into Canada and 49 European countries.

Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »